Duchenne Muscular Dystrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the DMD market through 2033.
Duchenne muscular dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle degeneration due to mutations in the dystrophin gene. Dystrophin is part of a group of proteins, which together form the dystrophin-associated protein complex (DPC). These proteins form a transmembrane scaffold that is crucial for the structure of the muscle tissue, protecting muscle fibers from injury during muscle contraction and relaxation. DMD is an X-linked recessive disorder mainly affecting males, with female carriers.
The DMD market across the 7MM was valued at $2.3 billion in 2023. Over the 10-year forecast period, the market is projected to grow at a CAGR of 8.5%, reaching $5.2 billion by 2033. The major driver for this growth will be the launch of several pipeline agents: Roche’s gene therapy, Capricor’s cell therapy deramiocel, PTC Therapeutics’ ataluren in the US, and other first-in-class therapies.
Scope
Overview of DMD, including epidemiology, symptoms, diagnosis, and disease management.
Annualized DMD treatment market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the DMD therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DMD treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
Analysis of the current and future market competition in the global DMD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecasts includes the 7MM
Forecasts covers from 2023-2033
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM DMD therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM DMD therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Nippon Shinyaku Co Ltd
NS Pharma Inc
PTC Therapeutics Ltd
Santhera Theraeputics
Catalyst Pharmaceuticals Inc
Italfarmaco SpA
Capricor Therapeutics Inc
Roche (F. Hoffmann-La Roche)
Taiho Pharmaceutical
Edgewise Therapeutics
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Duchenne Muscular Dystrophy reports